
|Articles|March 9, 2010
- December 2009
- Volume 0
Amgen Honored for Best Pipeline & Best New Drug
Author(s)Onclive Team
Advertisement
Articles in this issue
almost 16 years ago
Do Insurers Spend Too Much on Administration and Too Little on Care?almost 16 years ago
The Effect of New Treatments on Cancer-related Bone Lossalmost 16 years ago
Exercise Maintains Function, Improves QoL for Patients With Lymphomaalmost 16 years ago
Continuing Education Opportunities on the Webalmost 16 years ago
News Briefs & FDA Updatesalmost 16 years ago
News & Opinionalmost 16 years ago
Decline in Cancer Deaths No Reason to Get ComplacentAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
5



































